Publications & Presentations

The Wound Treatment Center, LLC @ Opelousas General Health System attended the Symposium for Advanced Wound Care in Atlanta, GA
April 13-17, 2016

Kerry T. Thibodeaux, MD, FACS, and Marcus S. Speyrer, RN, CWS had 2 poster abstracts that were chosen. The first poster was Epidermal Grafting Use in Complex Wound Closure at a Wound Care Center and the second was Negative Pressure Wound Therapy with Installation Use in a Wound Care Center. Both poster abstracts were sponsored by Acelity™.

Epidermal Grafting Use in Complex Wound Closure at a Wound Care Center Negative Pressure Wound Therapy with Installation Use in a Wound Care Center

Flow-through Instillation of Hypochlorous Acid in Treatment of Necrotizing Fasciitis
February 2016

Abstract: Introduction. Necrotizing fasciitis (NF) is a rare and rapidly progressing bacterial infection of soft tissues. Bacterial toxins cause local tissue damage and necrosis, as well as blunt immune system responses. A self-propagating cycle of bacterial invasion, toxin release and tissue destruction can continue until substantial amounts of tissue become necrotic. Neutralization of bacterial toxins should improve the results. Materials and Methods. Pure hypochlorous acid (HOCl) (0.01% w/v) with no sodium hypochlorite impurity in saline pH 4-5, which was recently shown to both eradicate bacteria and neutralize bacterial toxins in vitro, was administered via flowthrough instillation to 6 patients with NF 4-6 times daily as needed. Utilizing a vacuum-assisted closure, 5-10 mL of pure 0.01% HOCl with no sodium hypochlorite impurity was instilled and removed frequently to irrigate the wounds. Results. Of the 6 patients, no deaths or limb amputations occurred. All infected areas healed completely without major complications. Conclusion. The toxicity and immune dysfunction caused by bacterial toxins and toxins released from damaged cells may be mitigated by flow-through instillation with saline containing pure 0.01% HOCl with no sodium hypochlorite impurity. Randomized controlled clinical trial research of this relatively simple and inexpensive instillation protocol is suggested for identified cases of NF.


First North American Make America Better Summit: September 2015

Kerry T. Thibodeaux, MD, FACS and Marcus S. Speyrer, RN, CWS from The Wound Treatment Center, LLC at Opelousas General Health System recently attended on September 10-12, 2015 the “First North America Make Better Summit” sponsored by Acelity™ in Chicago, IL. Both were invited as faculty to present on economic impacts of wound centers and advanced wound dressings.

Acelity™ is a globally diversified wound care and regenerative medicine company, advancing the science of healing and restoring people’s lives. The 2015 “Make Better Summit” explored current issues surrounding cultural changes and clinical innovation in North America. Innovation is important for health care; it can transform patient outcomes, improve quality and productivity and is good for economic growth.

The “Make Better Summit” allowed clinicians to share clinical techniques and the implications for patients. It also allowed for excellent networking opportunity between clinical colleagues and the opportunity to ask global experts for best practice advice.

Persistent Wounds Find Hope for Healing Here
Featured In: Opelousas Magazine

"Complicated wounds can be hard to treat in an office environment, so Opelousas General Health System [OGHS] established a hospital-based wound care program,” says Dr. Kerry Thibodeaux, Medical Director of The Wound Treatment Center at OGHS. Since then, more than 125,000 wound care patients have benefited from this comprehensive, multidisciplinary approach that draws upon the expertise of surgeons, nutritionists, interventionists, nurses, infectious disease specialists, and other expertly trained staff."


Issue: 10: October 2010
Author: Kerry Thibodeaux, MD, FACS; S. William Tam, PhD

Abstract: The following case series includes a surgical excision, a burn wound, and a chronic venous ulcer that were successfully treated with Sepaderm®, a new wound management system. Sepaderm was chosen for its ease of use and its ability to remove excess exudate from the wound bed. The system also limits exudate leakage onto periwound tissue and protects against direct contact with the wound bed. These cases provide initial evidence that the Sepaderm system performed well and facilitated healing of different wound types, including a previously nonhealing venous leg ulcer.


Issue: March 2012
Author: Kerry Thibodeaux, MD, FACS; S. William Tam, PhD

Abstract: Recent preliminary studies have shown Sepaderm to be well tolerated and useful for the treatment of chronic, lower-extremity ulcerations, burn wounds, surgical excisions, chronic abdominal ulcers of hematoma origin, and chronic pressure ulcers. To confirm these initial findings, 18 cases of venous leg ulcers were treated with Sepaderm in conjunction with compression bandages. Patients had a mean age of 54.9 ± 13.5 years, and 78.9% were men. Six of the patients had previous standard treatments and 12 patients had Sepaderm as their initial treatment. Treatment duration with Sepaderm ranged from 6 to 90 days with a mean of 44.3 ± 25 days. The system was changed every 3 to 8 days depending on the amount of exudate. All the wounds responded positively with either partial or complete closure during treatment. Importantly, no patient experienced pain during the treatment. These findings suggest that Sepaderm may be effective for the treatment of venous leg ulcers.